IL132380A0 - Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods - Google Patents

Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods

Info

Publication number
IL132380A0
IL132380A0 IL13238098A IL13238098A IL132380A0 IL 132380 A0 IL132380 A0 IL 132380A0 IL 13238098 A IL13238098 A IL 13238098A IL 13238098 A IL13238098 A IL 13238098A IL 132380 A0 IL132380 A0 IL 132380A0
Authority
IL
Israel
Prior art keywords
protein
conjugates
antibody
compositions
chain
Prior art date
Application number
IL13238098A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/059,467 external-priority patent/US20020019352A1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL132380A0 publication Critical patent/IL132380A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IL13238098A 1997-04-17 1998-04-16 Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods IL132380A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84397197A 1997-04-17 1997-04-17
US09/059,467 US20020019352A1 (en) 1997-04-17 1998-04-14 Stable, active, human ob protein compositions and methods
PCT/US1998/007828 WO1998046257A1 (en) 1997-04-17 1998-04-16 Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods

Publications (1)

Publication Number Publication Date
IL132380A0 true IL132380A0 (en) 2001-03-19

Family

ID=26738785

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13238098A IL132380A0 (en) 1997-04-17 1998-04-16 Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods

Country Status (11)

Country Link
EP (1) EP0977583B1 (cg-RX-API-DMAC10.html)
JP (1) JP4086908B2 (cg-RX-API-DMAC10.html)
CN (1) CN1202862C (cg-RX-API-DMAC10.html)
AT (1) ATE223229T1 (cg-RX-API-DMAC10.html)
AU (1) AU7132798A (cg-RX-API-DMAC10.html)
CA (1) CA2286098C (cg-RX-API-DMAC10.html)
DE (1) DE69807679T2 (cg-RX-API-DMAC10.html)
ES (1) ES2183351T3 (cg-RX-API-DMAC10.html)
HU (1) HU226175B1 (cg-RX-API-DMAC10.html)
IL (1) IL132380A0 (cg-RX-API-DMAC10.html)
WO (1) WO1998046257A1 (cg-RX-API-DMAC10.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
CA2236163A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
ATE348163T1 (de) 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU1134000A (en) * 1998-10-27 2000-05-15 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
EP1278778A2 (en) * 2000-05-03 2003-01-29 Amgen Inc., Modified peptides, comprising an fc domain, as therapeutic agents
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
WO2002057435A2 (en) * 2001-01-18 2002-07-25 Merck Patent Gmbh Bifunctional fusion proteins with glucocerebrosidase activity
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
MXPA04011470A (es) 2002-05-21 2005-02-14 Amgen Inc Compuestos heterociclicos sustituidos y metodos de uso.
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
KR101163424B1 (ko) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Il-7 융합 단백질
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
KR20110028457A (ko) 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
CA2742600A1 (en) 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CN111529535A (zh) 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
PT3074033T (pt) 2013-11-26 2019-02-08 Childrens Medical Ct Corp Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
DK3509624T3 (da) 2016-09-12 2023-11-13 Amryt Pharmaceuticals Inc Fremgangsmåder til detektering af anti-leptin-neutraliserende antistoffer
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559208A (en) * 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
IL124831A0 (en) * 1995-12-27 1999-01-26 Genentech Inc Ob protein derivatives having prolonged half-life
EP1835030A1 (en) * 1996-12-20 2007-09-19 Amgen, Inc. OB fusion protein compositions and methods

Also Published As

Publication number Publication date
WO1998046257A8 (en) 2000-01-27
DE69807679D1 (de) 2002-10-10
HUP0002831A2 (hu) 2000-12-28
EP0977583A1 (en) 2000-02-09
JP2002512612A (ja) 2002-04-23
WO1998046257A1 (en) 1998-10-22
HUP0002831A3 (en) 2005-11-28
ES2183351T3 (es) 2003-03-16
AU7132798A (en) 1998-11-11
CA2286098A1 (en) 1998-10-22
EP0977583B1 (en) 2002-09-04
ATE223229T1 (de) 2002-09-15
CN1274289A (zh) 2000-11-22
JP4086908B2 (ja) 2008-05-14
HK1023513A1 (en) 2000-09-15
HU226175B1 (en) 2008-06-30
CA2286098C (en) 2009-07-07
DE69807679T2 (de) 2003-07-31
CN1202862C (zh) 2005-05-25

Similar Documents

Publication Publication Date Title
HUP0002831A2 (hu) Az ellenanyag Fc láncával konjugátumot alkotó humán OB fehérjéket tartalmazó stabilis, aktív összetételek és előállítási eljárásaik
NZ332625A (en) Concentrated antibody preparation containing greater than 100 mg/ml of the antibody
DE69432758D1 (en) Therapeutisch wirksame peptidderivate
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
EP1439193A3 (en) Antibody directed to polypeptide having heparanase activity
EP1752465A3 (en) Linear VH-CH1-VH-CH1 heavy chain antibody fragment
DE69330643D1 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
AU2349697A (en) Monoclonal antibodies against the interferon receptor with neutralizing activity against type I interferon
ATE354644T1 (de) Katalytischer antikörper gegen aldolase
CA2246715A1 (en) Antibody variants
EP2275540A3 (en) Method for controlling the activity of immunologically functional molecule
PT969873E (pt) Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso
AU2236795A (en) Afamin: a human serum albumin-like protein
WO1996027665A3 (en) Neuron-restrictive silencer factor proteins
EP0725081A4 (en) MONOCLONAL ANTIBODY AGAINST MxA OF HUMAN Mx PROTEIN
WO1999024835A3 (en) An immunoassay for procollagen-iii-c-terminal propeptide
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
EP1023906A4 (en) POTENTIATOR FOR ANTI-TUMOR ANTIBODY LYMPHOID
CA2128833A1 (en) P53as protein and antibody therefor
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
DE59509948D1 (de) Konjugat aus einem wirkstoff und einem nicht als körperfremd angesehenen, nativen protein
EP0918796A4 (en) MONOCLONAL ANTIBODY FOR AGGLUTINATION BY E. COLI, CONTAINING A PROTEIN FROM THE CS4 / CFA FAMILY
AU3283693A (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy
ATE293996T1 (de) Lage-spezifische markierung von disulfide- enthaltenden zielgerichteten vektoren
AU2002300605A1 (en) Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed